Telmisartan Market by Indication (Hypertension and Cardiovascular Risk Reduction) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global telmisartan market was valued at $3,453 million in 2019, and is projected to reach $4,258 million by 2027, registering a CAGR of 3.4% from 2020 to 2027.
Telmisartan drug is a non-peptide angiotensin receptor blocker (ARB) used alone or in combination with other agents such as hydrochlorothiazide and amlodipine, for treatment of hypertension. Moreover, it is used in treatment of cardiovascular risk reduction. Telmisartan is available in tablets of different strengths such as 20, 40 and 80 mg tablets under the trade name Micardis. In addition, telmisartan tablet is available in generic forms. The daily dose of telmisartan for hypertension is 40 to 80 mg and for cardiovascular risk reduction it is 80 mg. These drugs are prescribed by a physician, and are available in retail stores, online pharmacies, and hospital pharmacies.
The growth of the global telmisartan market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension and cardiovascular is another major factor that fuels the growth of the market. In addition, surge in geriatric population and sedentary lifestyle act as key drivers of the global market. Moreover, increase in approval for abbreviated new drug application (ANDA) for manufacturing of generic telmisartan tablets and rise in cases of chronic kidney disease is expected to propel growth of telmisartan market. However, drug shortages are expected to restrain the growth of the telmisartan market. Conversely, surge in research related to telmisartan drug in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global telmisartan market is segmented into indication, distribution channel, and region. On the basis of indication, the market is categorized into hypertension and cardiovascular risk reduction. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA
KEY BENEFITS FOR STAKEHOLDERS • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of four regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Indication • Hypertension
• Cardiovascular Risk Reduction
By Distribution Channel • Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Pharmacies
By Region • North America
o Rest of Europe
o Rest of Asia-Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT • Abbott Laboratories
• Aurobindo Pharma
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• Glaxosmithkline Plc (GSK)
• Mylan N.V.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd. (Actavis Generics)
• Zydus Cadila
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.) • Solco Healthcare
• Hikma Pharmaceuticals PLC
• Torrent Pharmaceuticals Ltd.
Our reports have been used by over 10K customers, including:
Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc. Although the manufacturing of generic injectables is complex, their R&D...
The Global Telmisartan Market size is expected to reach $4 billion by 2026, rising at a market growth of 5.8% CAGR during the forecast period. Telmisartan refers to an angiotensin receptor blocker (ARB) utilized alone or combined with other agents in order to treat stroke management, cardiac arrest, and hypertension. Telmisartan is available...
Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021 provides...
Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity...
Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021 provides...
Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 184.108.40.206) - Drugs in Development, 2021 Summary Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 220.127.116.11) - Drugs...
The global generic drugs market reached a value of US$ 386 Billion in 2020. A generic drug is a medicine that contains the same active ingredient and has an equivalent therapeutic effect as the branded drug. It is also identical in terms of safety, quality, dosage, strength, route of administration, intended use, effect,...
The global generic oncology drugs market exhibited strong growth during 2015-2020. Generic oncology drugs assist in shrinking, controlling and destroying the cancer cells present in the human body. Furthermore, a few oncology drugs are widely prescribed by doctors to alleviate symptoms, including pain. They share the...
689 pages •
By Global Industry Analysts
• Apr 2021
- Growing Competition in Consumer Markets, Plethora of Products With Myriad Claims Means Consumers Increasingly Want Proof of Efficacy. Efficacy Testing to Reach $866.3 Billion
- The global market for Efficacy Testing is projected to reach US$866.3 million by the year 2027, trailing a post COVID-19 CAGR...
285 pages •
By Global Industry Analysts
• Apr 2021
- Global Generic Drugs Market to Reach $535.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$286 Billion in the year 2020, is projected to reach a revised size of US$535.5 Billion by 2027, growing at aCAGR of 9.4% over the period 2020-2027. Pure Generic Drugs,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.